Nothing said here yet.
to join the conversation.
| Kroeger Christopher A.Chief Executive Officer | Sell | 73,691 | $595.4K | Thu, Oct 15 |
| Foff Erin PennockChief Medical Officer | Sell | 15,355 | $124.1K | Thu, Oct 15 |
| Kreitzer AnatolChief Discovery Officer | Sell | 12,248 | $96.0K | Thu, Oct 15 |
| Lillie James WoodruffChief Scientific Officer | Sell | 11,513 | $93.0K | Thu, Oct 15 |
| GILLIS JONATHANCAO and Interim CFO | Sell | 10,167 | $82.1K | Thu, Oct 15 |
| Hanson KristopherGeneral Counsel | Sell | 9,020 | $72.9K | Thu, Oct 15 |
| Hanson KristopherGeneral Counsel | Sell | 16,509 | $192.7K | Wed, Sep 16 |
The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now.
MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:
Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA…
MapLight Therapeutics (MPLT) said Thursday it has signed an agreement with investors to sell securit
SAN FRANCISCO and BOSTON, Aug. 13, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc.
MapLight said the twice-daily dose met the primary endpoint of the schizophrenia trial, but the daily dose did not.
MapLight announced topline findings from its mid-stage ZEPHYR trial of ML-007C-MA, an oral medicine tested in about 307 adults hospitalized for a sudden worsening of schizophrenia symptoms, on Monday.
Maplight Therapeutics (NASDAQ:MPLT) reported that its Phase II ZEPHYR trial of ML-007C-MA met its primary endpoint in schizophrenia, with the twice-daily regimen producing a statistically significant improvement in Positive and Negative Syndrome Scale, or…
The trial, designed and sized to support registration, met its primary endpoint, with the 210/3 mg BID dose demonstrating a statistically significant improvement in PANSS total score compared to placebo at Week 5 with an effect size of 0.37 (LS mean…
MapLight Therapeutics (MPLT) has drawn fresh attention after recent trading left the stock at $36.56, with gains over the past month and past three months contrasting with a mixed shorter term performance. See our latest analysis for MapLight Therapeutics.